P-MUC1C-101
/ Roche
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
October 14, 2020
[VIRTUAL] P-MUC1C-ALLO1: An Allogeneic CAR-T for Multiple Solid Tumor Indications
(SITC 2020)
- "In assay of stable P-MUC1C-101 CAR-T cells, more than 95% expressed CAR, and were comprised of an exceptionally high-percentage of TSCM cells (CD45RA+CD62L+CD45RO-)...P-MUC1C-ALLO1 displayed in vitro specificity for tumor vs normal cells, and in vivo efficacy against xenograft models of breast and ovarian cancer. We anticipate an IND filing and initiation of a Phase 1 clinical trial in 2021."
Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • Triple Negative Breast Cancer • B2M • IFNG • MUC1
October 14, 2020
[VIRTUAL] P-MUC1C-ALLO1: An Allogeneic CAR-T for Multiple Solid Tumor Indications
(SITC 2020)
- "In assay of stable P-MUC1C-101 CAR-T cells, more than 95% expressed CAR, and were comprised of an exceptionally high-percentage of TSCM cells (CD45RA+CD62L+CD45RO-)...P-MUC1C-ALLO1 displayed in vitro specificity for tumor vs normal cells, and in vivo efficacy against xenograft models of breast and ovarian cancer. We anticipate an IND filing and initiation of a Phase 1 clinical trial in 2021."
Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • Triple Negative Breast Cancer • B2M • IFNG • MUC1
1 to 2
Of
2
Go to page
1